IGM Biosciences is pioneering a new class of antibody medicines for the treatment of autoimmune and inflammatory diseases. Building upon the greater binding power provided by the naturally occurring IgM antibody structure, as compared with the commonly used IgG antibody structure, IGM has been able to create “super antibodies” with the potential to generate novel therapeutic options and hope for patients.
REIMAGINING
antibody medicines
Reimagining antibody medicines
We believe we have the world’s most advanced research and development program focused on engineered therapeutic IgM antibodies.
Using our expertise to expand upon and improve the inherent qualities of IgM antibodies and produce them at scale, we aim to develop a range of therapeutic antibodies for the treatment of autoimmune and inflammatory diseases.
Exploring scientific boundaries
By developing this new class of antibodies,
we have opened up new approaches to treating disease.
Make an impact at IGM
Help us bring a new class of antibody medicines to patients.
Recent News
November 8, 2024
November 4, 2024
Featured
Abstract #1533: Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, Effectively Depletes Low-Expressing CD20+ B Cells in Preclinical Models of Autoimmune Disease
Poster presented at ACR Convergence, 17 November 2024
Cutting-edge approaches to B-cell depletion in autoimmune diseases
Front. Immunol., 08 October 2024
Therapeutic Potential of Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, for the Treatment of Refractory Autoimmune Disease Patients
